Palo Santo, a venture fund focused on psychedelic therapeutics and a Ksana Health investor, took a survey of the perspectives of a number of thought leaders in the psychedelics space in light of the ongoing crisis of distress and violence going on in the US. One of the thought leaders was Ksana Health founder, Dr. Nick Allen, PhD. The healthful potential of psychedelics will be limited if ethical and complementary technologies are not used alongside them.
At Ksana Health, we believe in the potential of continuous behavior measurement & intervention to provide treaters and the treated a richer insight into the moment-to-moment experience and effect of psychedelic therapy. This rich real-world measurement will make for better therapeutic experiences, optimizations, and alliances. We have recently entered an agreement with Beckley PsyTech to aid their Phase 2 trials.
19 August 2022
Contributed by Lauren Weiner, Ksana Health Director of Clinical Science. On June 21, 2023, Ksana Health recently attended the 2023 Society for Digital Mental Health Conference. The event highlighted the role of...Continue reading
Ksana Health is jazzed to be selected to join the Beyond Language Studio, a collaboration between Sorenson and Newlab supporting deep-tech startups building high-impact, innovative products, and services through real-world pilot projects. The...Continue reading
For Ksana Health, 2022 was a year of perseverance, learning and optimization. We are grateful to all the partners, collaborators and supporters who made the year what it was. The video below...Continue reading